ENTITY

Celyad SA (CYAD BB)

18
Analysis
Health CareBelgium
Celyad Oncology SA is a bio-pharmaceutical company. The Company specialized in CAR-T cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis, such as cancer. Celyad Oncology serves customers worldwide.
more
bullishCelyad SA
07 Dec 2018 18:38Issuer-paid

Celyad - Blasts get blasted but dose needs definition

Data at ASH on 3 December confirmed that CYAD-01 T-cells can destroy acute myeloid leukaemia (AML) blast (cancer) cells. In eight reported AML...

Share
bullishCelyad SA
04 Dec 2018 00:05Issuer-paid

Celyad - Allogeneic trial first dose given

The allogeneic version of NRK CAR T-cell therapy, CYAD-101, is underway with the first patient dosed. The study mirrors the current colorectal...

Share
bullishCelyad SA
27 Nov 2018 16:35Issuer-paid

Celyad - Highly encouraging data on dose responses

Celyad has presented an update on its CYAD-01 solid cancer trials with haematological data due in early December. There are strong indications that...

Share
bullishCelyad SA
02 Aug 2018 22:23Issuer-paid

Celyad - Allogeneic trial approved in colorectal cancer

The FDA’s sign off on Celyad’s first clinical trial design for its allogeneic NRK CAR T-cell therapy (CYAD-101) is an important milestone. The...

Share
bullishCelyad SA
21 Jun 2018 15:43Issuer-paid

Celyad - Developing a sophisticated clinical strategy

Celyad has reached the potentially crucial three billion natural killer receptor (NKR) CAR T-cell dose (CYAD-01) in acute myeloid leukaemia (AML)...

Share
No more insights
x